Gallstone, cholecystectomy and risk of gastric cancer

Sung Hwa Kang 1, Young Hoon Kim 1, Young Hoon Roh 1, Kwan Woo Kim 1, Chan Joong Chol 1, Min Chan Kim 1, Su Jin Kim 1, Hee Jin Kwon 2, Jin Han Cho 2, Jin Seok Jang 3, and Jong Hun Lee 3

1Department of Surgery, 2Department of Radiology, 3Department of Internal Medicine, Dong-A University Hospital, Busan, Korea

Backgronds/Aims: The aim of this retrospective study is to compare stomach cancer incidence, characteristics between gallstones, cholecystectomy and control groups. It also aims to investigate key variables' potential effects on overall survival. Methods: A total of 99 patients, diagnosed with stomach cancers between April 1994 and December 2015, were identified. We excluded stomach cancer patients, accrued during the first year of follow-up in both the gallstones and cholecystectomy groups, assuming that they missed cancers. The main analyses addressing the objective were a chi-square analysis and a survival analysis. Results: The incidence of stomach cancers was increased in both the gallstone and cholecystectomy groups, compared with the control group ( p=0.003). Multivariate regression analysis showed that the overall survival in gallstones, cholecystectomy group patients as compared with those in the control group decreased (HR=6.66, 95 CI: 1.94-22.80, p=0.003). Also, T-stage was found to statistically affect the rate of overall survival (HR=9.85, 95% CI: 3.09-31.39, p=0.000). The stomach cancer showed the worse survival at the posterior, greater curvature location than anterior, lesser curvature of the stomach (HR=0.30, 95% CI: 0.11-0.80, p=0.017). Conclusions: We provided an awareness of the possible increased risks of stomach cancer in gallstone and cholecystectomy group patients, which might be induced by duodenogastric bile reflux. Also, the survival rate was poor ( p<0.000). Therefore, close follow-up strategies for early detection are recommended for such patients. (Ann Hepatobiliary Pancreat Surg 2017;21:131-137)

Key Words: Stomach cancer; Gallstones; Cholecystectomy

INTRODUCTION

Gallstone disease poses significant health problems. In Asia, westernization of the diet and socioeconomic status have changed the patterns of gallstone disease. 1 Cholecystectomy is the treatment of choice for symptomatic gallstones. After the adoption of noninvasive laparoscopic cholecystectomy, the number of cholecystectomies has increased worldwide. Stomach cancer is the fifth most common cancer in the world— and the highest incidences have been in East Asia, China, Eastern Europe, Latin America, and the Caribbean. 2

In healthy individuals, 75-80% of hepatic bile enters the gallbladder and only 20-25% of bile directly enters into the duodenum. In cases of chronic calculous cholecystitis, 30-40% of hepatic bile enters the gallbladder and 60-70% of hepatic bile passes into the duodenum (due to the decreased rate of water absorption in the gallbladder wall). Following cholecystectomy, 100% of the hepatic bile enters the duodenum (Fig. 1). 3

During the process of enterohepatic circulation, anaerobic bacteria promote 7α-dehydroxylation of hydrophilic primary bile acids (cholic acid and chenodeoxycholic acid), converting them into hydrophobic secondary bile acids (deoxycholic acid [DCA] and lithocholic acid).

Depending on the concentration, hydrophobic secondary bile acids can cause cholestasis and necrosis or promote apoptosis and DNA damage. Furthermore, DCA is not only mutagenic but carcinogenic. Taken together, the evidence suggests that the human gallbladder fulfills a protective function. The gallbladder decreases the formation of secondary hydrophobic hepatotoxic bile acids
by accumulating primary bile acids thereby, protecting the liver and the mucosa of the stomach.4

Based on the biological mechanism described above, we hypothesized that gallstones, cholecystectomy would be associated with an increased risk of stomach cancers, and evaluated the association of gallstones, cholecystectomy with stomach cancer in a hospital-based case-control study.

MATERIALS AND METHODS

Study sample

A total of 99 patients newly diagnosed with stomach cancers were enrolled in this study. Between April 1994 and December 2015, we identified 5,566 patients whose records contained a cholecystectomy code (International Classification of Disease, Ninth Revision). The gallstones group consisted of 6,891 patients who had a diagnosis of gallstones and were not cholecystectomized.

To reduce the effect of selection bias, we excluded stomach cancers, which appeared during the first year of follow-up either cholecystectomy or after a diagnosis of non-surgically-treated gallstones. This was done for the detection of stomach cancer cases identified only because of gallstones and cholecystectomy.

Control patients who voluntarily visited the Dong-A University Hospital Health Care System, for a health check-up between June 2007 and December 2015 were enrolled. As a part of these health care programs, patients were routinely screened with ultrasonography. Of the 37,236 initially enrolled patients, 2,525 foreign patients or gallstone patients were excluded. Therefore, 34,711 control patients were included in this analysis. We retrospectively reviewed the patient’s medical records.

Immunohistochemical studies

Immunohistochemical chemistry was used as diagnostic aids, prognostic or predictive indicators, or histogenetic probes. The p53 protein was detected for genomic stability. CD10 and MUC2 mucin were used as biomarkers for the identification of intestinal metaplasia. MUC5AC and MUC6 mucins were used as biomarkers for the identification of gastric goblet epithelium. CD31 was used as a biomarker for the identification of endothelial cells.

Endoscopic finding

We determined the level of each stomach cancer (cardia or non-cardia), along with the location of each (posterior, greater curvature, anterior, lesser curvature). Usually, due to the flow and gravity of bile juice, duodenogastric-bile-reflux-induced stomach cancers were located in the posterior, greater curvature of the stomach with greater frequency than in the anterior, and lesser curvature of the stomach.

Statistical analysis

Variables were summarized by frequency and percentage for the categorical data. A mean±standard test or Fisher’s exact test was used for categorical data. An independent t-test was used for numeric data. Overall survival (OS) was estimated using Kaplan-Meier curves.

Survival curves were compared between groups using the log-rank test. Multivariate analyses, using Cox regression, were performed in order to identify prognostic factors, which are independently related to overall survival. All statistical analyses were carried out using SPSS 22.0 (IBM Corp., Armonk, NY) and MedCalc 11.6.0 (MedCalc, Mariakerke, Belgium) statistical software. P values of less than 0.05 were considered to be statistically significant. By its nature, this study was explorative. Therefore, no adjustment for multiple testing was applied.

RESULTS

The demographic characteristics of stomach cancers are
shown in Table 1.

The gender distribution was 31.1% male and 68.7% female. The mean age was 61.7±13.1 years. The patients in both the gallstone group and cholecystectomy group were older than those in the control group (p=0.000). The median follow-up time was 53 months. The overall incidence rate of stomach cancer was higher in the gallstone and cholecystectomy groups than in the control group (p=0.003) (Fig. 2).

The median overall survival rate was shown to be worse in the gallstone and cholecystectomy group than in the control group (p=0.000) (Fig. 3).

The prevalence of comorbidities—especially hypertension and cerebrovascular comorbidities—was greater in

### Table 1. Baseline characteristics of the stomach cancer patients

| Variable                        | Overall          | GB(−)/GB(+) | Control | Group | p-value |
|---------------------------------|------------------|-------------|---------|-------|---------|
| All patients (n, %)             | 99 (100.0)       | 39 (39.4)   | 60 (60.6)|       |         |
| Sex (n, %)                      |                  |             |         |       |         |
| Male                            | 31 (31.3)        | 10 (25.6)   | 21 (35.0)| 0.327 |
| Female                          | 68 (68.7)        | 29 (74.4)   | 39 (65.0)|       |         |
| Age (<65, years) (n, %)         | 61.7±13.1        | 71.9±10.3   | 55.1±10.2| 0.000 |
| ≥65                             | 56 (56.6)        | 8 (20.5)    | 48 (80.0)| 0.000 |
| Comorbidity (n, %)              |                  |             |         |       |         |
| DM                              | 24 (24.2)        | 10 (25.6)   | 14 (23.3)| 0.793 |
| HTN                             | 27 (27.3)        | 16 (41.0)   | 11 (18.3)| 0.013 |
| CVA                             | 8 (8.1)          | 7 (17.9)    | 1 (1.7)  | 0.006 |
| MI                              | 10 (10.1)        | 5 (12.8)    | 5 (8.3)  | 0.509 |
| No                              | 43 (43.4)        | 10 (25.6)   | 33 (55.0)| 0.004 |
| Multiple lesion (n, %)          |                  |             |         |       |         |
| No                              | 91 (91.9)        | 34 (87.2)   | 57 (95.0)| 0.257 |
| Yes                             | 8 (8.1)          | 5 (12.8)    | 3 (5.0)  |       |
| Combined cancer (n, %)          |                  |             |         |       |         |
| No                              | 83 (83.8)        | 28 (71.8)   | 55 (91.7)| 0.009 |
| Yes                             | 16 (16.2)        | 11 (28.3)   | 5 (8.4)  |       |
| Treatment (n, %)                |                  |             |         |       |         |
| EMR, ESD                        | 31 (31.3)        | 8 (20.5)    | 23 (38.3)| 0.061 |
| Others                          | 68 (68.7)        | 31 (79.5)   | 37 (41.7)|       |
| Recurrence (n, %)               |                  |             |         |       |         |
| Yes                             | 26 (26.3)        | 19 (48.7)   | 7 (11.7) | 0.000 |
| No                              | 73 (73.7)        | 20 (51.3)   | 53 (88.3)|       |
| Death (n, %)                    |                  |             |         |       |         |
| NED, AWD                        | 72 (72.7)        | 18 (46.1)   | 54 (90.0)| 0.019 |
| DOD                             | 27 (27.3)        | 21 (53.8)   | 6 (10.0) |       |
| Tumor level (n, %)              |                  |             |         |       |         |
| Cardia                          | 9 (9.1)          | 4 (10.3)    | 5 (8.3)  | 0.765 |
| Non-cardia                      | 90 (90.9)        | 35 (89.7)   | 55 (91.7)|       |
| Tumor location (n, %)           |                  |             |         |       |         |
| Anterior lesser curvature        | 54 (45.5)        | 23 (59)     | 31 (51.6)| 0.476 |
| Posterior greater curvature     | 45 (54.5)        | 16 (41.1)   | 29 (48.4)|       |
| Differentiation (n, %)          |                  |             |         |       |         |
| Well                            | 35 (35.4)        | 13 (33.3)   | 22 (36.7)| 0.136 |
| Moderate                        | 32 (32.3)        | 10 (25.6)   | 22 (36.7)|       |
| Poorly                          | 32 (32.3)        | 16 (41.1)   | 16 (26.6)|       |
| Lauren classification (n, %)    |                  |             |         |       |         |
| Intestinal                      | 62 (62.6)        | 19 (48.7)   | 43 (71.7)| 0.022 |
| Diffuse                         | 30 (30.3)        | 18 (46.2)   | 12 (20.0)|       |
| Mixed                           | 7 (7.1)          | 2 (5.1)     | 5 (8.3)  |       |

DM, diabetes mellitus; HTN, hypertension; CVA, cerebrovascular accident; MI, myocardial infarction; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; NED, no evidence of disease; AWD, alive with disease; DOD, death of disease; GB(−), after cholecystectomy; GB(+), gallstones
Fig. 2. Comparison of stomach cancer incidence between the groups. GB(−), cholecystectomy; GB(+), gallstones.

Fig. 3. Overall patient survival rate, according to the groups. GB(−), cholecystectomy; GB(+), gallstones.

The incidence of different types of combined malignancies (4 colon cancers, 4 lung cancers, 3 thyroid cancers, 3 pancreatic cancers, and 2 hepatocellular carcinomas), was more frequent in the gallstone and cholecystectomy groups than in the control group (p=0.004).

The level of stomach cancer (cardia or non-cardia) (p=0.765) and its location (posterior, greater curvature versus anterior, lesser curvature) (p=0.476), showed insignificant statistical differences. The differentiation of stomach cancer showed an insignificant statistical difference between the groups; but in the Lauren classification, the intestinal type was more frequent in the control group (p=0.022).

Immunohistochemical studies P53, CD10, MUC2, M5AC, MUC6, and CD 31 showed insignificant statistical differences between gallstone and cholecystectomy groups, and the control group (Table 2).

Treatment modalities for stomach cancer such as endoscopic mucosal resection and endoscopic submucosal dissection—along with other modalities—were compared; but no statistical differences were observed between the groups (p=0.061).

Hazard ratios (HR) and 95% confidence intervals (CI) were calculated for death, using a multivariate Cox regression model.

The HR for OS in the gallstone and cholecystectomy patients as compared with that in control patients is 6.656 (p=0.003: 95% CI, 1.94-22.80) Also, tumor (T)-stage was found to affect OS statistically (HR=9.85: 95% CI, 3.09-31.39: p=0.000).

Patients with stomach cancers in the posterior, greater curvature location of the stomach showed worse OS than did those with cancers in the anterior, lesser curvature location of the stomach (HR=0.30: p=0.017: 95% CI, 0.11-0.80) (Table 3).

The gallstones and cholecystectomy group patients showed advanced stage cancer. Also, cancer in the posterior, greater curvature location of the stomach—which might be caused by duodenogastric bile reflux—results in a poor survival rate (p=0.017).

### Table 2. Immunohistochemical analysis of the stomach cancer patients

| Variable       | Overall | GB(−)/GB(+) | Control | p-value |
|----------------|---------|-------------|---------|---------|
| P53 (n, %)     |         |             |         |         |
| −              | 29 (43.9)| 7 (35.0)    | 22 (47.8)| 0.335   |
| +              | 37 (56.1)| 13 (65.0)   | 24 (52.2)|         |
| CD10 (n, %)    |         |             |         |         |
| −              | 49 (75.4)| 14 (77.8)   | 35 (74.5)| 1.000   |
| +              | 16 (24.6)| 4 (22.2)    | 12 (25.5)|         |
| MUC2 (n, %)    |         |             |         |         |
| −              | 51 (78.5)| 14 (77.8)   | 37 (78.7)| 1.000   |
| +              | 14 (21.5)| 4 (22.2)    | 10 (21.3)|         |
| MUC5AC (n, %)  |         |             |         |         |
| −              | 36 (55.4)| 10 (55.6)   | 26 (55.3)| 0.986   |
| +              | 29 (44.6)| 8 (44.4)    | 21 (44.7)|         |
| MUC6 (n, %)    |         |             |         |         |
| −              | 41 (64.1)| 13 (76.5)   | 28 (59.6)| 0.213   |
| +              | 23 (35.9)| 4 (23.5)    | 19 (40.4)|         |
| CD31 (n, %)    |         |             |         |         |
| −              | 37 (75.5)| 13 (72.2)   | 24 (77.4)| 0.738   |
| +              | 12 (24.5)| 5 (27.8)    | 7 (22.6)|         |

GB(−), after cholecystectomy; GB(+), gallstones
Table 3. Overall survival in gallstones, after cholecystectomy group patients as compared with subjects in the control group

| Variable                                                                 | HR  | 95% CI       | p-value |
|--------------------------------------------------------------------------|-----|--------------|---------|
| Group [GB(−)/GB(+)] vs. control                                          | 6.65| 1.94-22.80   | 0.003   |
| Sex (male vs. female)                                                    | 0.94| 0.37-2.42    | 0.900   |
| Age (>65 vs. ≤65)                                                        | 0.81| 0.29-2.44    | 0.704   |
| Comorbidity (yes vs. no)                                                 | 0.53| 0.19-1.45    | 0.215   |
| Multiple lesion (yes vs. no)                                             | 2.67| 0.76-9.35    | 0.126   |
| Combined cancer (yes vs. no)                                             | 1.31| 0.49-3.48    | 0.594   |
| Stage (T2, T3, and T4 vs. T1)                                            | 9.85| 3.09-31.39   | 0.000   |
| Level (others vs. lower)                                                 | 0.48| 0.19-1.20    | 0.116   |
| Location (anterior lesser curvature vs. posterior greater curvature)     | 0.30| 0.11-0.80    | 0.017   |
| Lauren (others vs. intestinal)                                          | 1.04| 0.37-2.98    | 0.936   |

GB(−), after cholecystectomy; GB(+), gallstones

In the multivariate Cox regression model, hazard ratios and 95% CIs were calculated for death. The HR for OS in GB(−)/GB(+) patients as compared with that of control patients is 2.04 (p=0.001; 95% CI, 1.33-3.13). Also, the T stage was found to statistically affect OS (HR=7.27; p=0.000; 95% CI, 3.17-16.66). Stomach cancers located in the posterior, greater curvature showed worse OS than did those located in the anterior, lesser curvature of the stomach (HR=0.30; p=0.017; 95% CI, 0.11-0.80)

DISCUSSION

The association of the gallstone and cholecystectomy group patients with stomach cancer suggests that exposure to bile may be an important carcinogenic mechanism. In the gallstone and cholecystectomy groups, the overall incidence of stomach cancer was higher in this study’s series—a finding which was consistent with other results.5-7 By contrast, other studies yielded data that conflicted with these results.8,9

The burdensome challenge of the prevalence of gallstones in western countries (ranging from 5.9% to 21.9% in the general population) has increasingly become a problem. A genetic link to cholesterol (30% of the genetic component being accounted for by “thrifty” genes) has been postulated and the associations among diabetes, obesity, and gallstones most likely come about through the metabolic syndrome.10

There has been a gradual increase in the incidence of gallstones in conjunction with the westernization of Korean lifestyle. As similar to that of other Asian countries, the prevalence of gallstones in the Korean population was 6.1%, and patients who underwent cholecystectomy had a 35% higher prevalence of non-alcoholic fatty liver disease.1-3 Chronic liver disease is a well-known risk factor for gallstones, diabetes mellitus, hepatitis B/C, and liver cirrhosis. Other risk factors for gallstones include certain drugs, total parenteral nutrition, fasting, and Crohn’s disease.

High exposure to bile acids is prevalent among individuals who have a high dietary fat intake. High bile acid exposure increases the production of reactive oxygen species, reactive nitrogen species, increased DNA damage, increased mutation, and reduced apoptosis upon chronic exposure. It is very likely that the same risk factors for gallstones and cancer—such as obesity, diet, ethnicity, family history, and cigarette smoking—coexist in patients. Unless such confounders are adjusted for, it is difficult to conclude that the risk is purely an effect of cholecystectomy alone.

The proposed mechanism for increased risk of stomach cancer in gallstones, cholecystectomy group is through alteration of bile flow, increased exposure, alteration of bile salts, and subsequent alteration of metabolic hormone levels. Bile is not only stored in the gallbladder but is also concentrated, so that the biliary output to the gut is approximately halved in the presence of a functioning gallbladder. After cholecystectomy, a large volume of bile can overload the clearing capacity of the proximal duodenum and thereafter cause duodenogastric reflux. In cholecystectomy, all the bile secreted from the liver drains through the sphincter of Oddi into the duodenum, producing a continuous flow, and resulting in increased transcapillary bile flow and a CBD emptying rate. This increased and continuous bile flow can lead to a reflux of bile into the stomach and the esophagus.

Post-cholecystectomy syndrome is characterized by the persistence of symptoms or an occurrence of new symp-
toms following cholecystectomy. Sphincter of Oddi dysfunction is one of the most important symptoms following cholecystectomy and may be caused by injury of the direct neural pathway between the gallbladder and duodenum—as has been demonstrated in a Suncus murinus, whole-mount immunohistochemical study. Some studies have suggested that the elimination of the gallbladder reservoir function following cholecystectomy, causes a change in the pattern of the bile flow into the duodenum, potentially increasing bile reflux into the stomach. One of the bile acids may be weak mutagen, whose cumulative effect could result in carcinogenesis after many years of exposure. Supporting evidence indicates that bile acids cause DNA damage and induce frequent apoptosis. After repeated apoptosis, the capability for the development of stomach cancer and esophageal adenocarcinoma and their actual documented incidences increase. However, other studies have demonstrated that cholecystectomy does not result in either increased bile reflux into the stomach or increased gastroesophageal reflux. The gallbladder regulates bile acid homeostasis, so a significant alteration in bile acid metabolite following cholecystectomy may alter glucose and lipid metabolism. Cholecystectomy increases enterohepatic circulation cycles and leads to greater enterohepatic circulation of estrogen, progesterone, and their active metabolites which cause inflammation, stimulate fat accumulation, lead to cholestasis, and induce breast cancer. Also, elevated circulating levels of cholecystokinin (CCK) have been identified and CCK has been shown to stimulate growth of human pancreatic cells. In a comprehensive review, no strong evidence was observed for association between cholecystectomy and subsequent development of cancers of the esophagus, pancreas, small bowel, and colon.

The function of P53 in response to DNA damage includes inducing cell cycle arrest, facilitating the DNA repair process, and promoting apoptosis. Thus, a reduction in P53 by DCA should increase genomic instability. DCA has also been shown to cause degradation of P53. CD10 and MUC2 are useful for the identification of intestinal metaplasia. MUC5AC and MUC6 are useful for the identification of gastric goblet epithelium. CD 31 is useful for identification of the endothelial cell. In this study, P53, CD10, MUC 2, M5AC, MUC6, and CD 31, showed only insignificant statistical differences between the gallstone, cholecystectomy, and control groups.

The question of whether prophylactic cholecystectomy during gastrectomy for cancers is needed remains a controversial issue. The reason for prophylactic cholecystectomy is the incidence of gallstones after gastrectomy was considerably higher than was the prevalence of gallstones detected during the health examination in Korea (2.3-4.9%). The main pathophysiologic mechanism is considered to be an interruption of the anterior hepatic branch of the vagus nerve—a condition which leads to bile juice stagnation. So, is prophylactic cholecystectomy needed? On the contrary, after gastrectomy, most patients—at least 75%—will not have gallstone disease and may possibly experience a functional digestive problem as a result of unnecessary cholecystectomy having been performed. Our results lend some support to the decision to avoid prophylactic cholecystectomy for the risk of stomach cancer, if indication for the surgery is uncertain.

This study provides more compelling results than do previous studies. Firstly, this study is a large-scale, hospital-based, case-control study. This study was based on a control group representative of the general population (considering the nature of the health screenings). Secondly, this study is not merely an epidemiological study, but a clinical study based on endoscopic findings, imaging results, immunohistochemical tests, and survival analyses for members of the Asian population. However, there are some limitations of this study. Firstly, the case-control design is more susceptible to recall and selection bias than is a cohort design. Secondly, retrospective studies such as this one generally tend to be lower in statistical quality than the findings of randomized controlled trials.

In conclusion, we suggest that there could be an awareness of the possibility of an increased risk for developing stomach cancer in gallstones, cholecystectomy patients, which might be induced by duodenogastric bile reflux. Moreover, as the characteristics of the stomach cancers were only detected once they had already progressed to an advanced stage, the survival rate was worse than for those in the control group. Therefore, close follow-up strategies for the early detection of stomach cancer are recommended in caring for these patients. Further studies are needed regarding the linkage between gallstones, chol-
ecystectomy, and stomach cancer.

ACKNOWLEDGEMENTS

This work was supported by the Dong-A University research fund.

REFERENCES

1. Lee YJ, Park KS, Cho KB, Kim ES, Jang BK, Chung WJ, et al. Shifting prevalence of gallbladder polyps in Korea. J Korean Med Sci 2014;29:1247-1252.
2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-1850.
3. Chen YK, Yeh JH, Lin CL, Peng CL, Sung FC, Hwang IM, et al. Cancer risk in patients with cholelithiasis and after cholecystectomy: a nationwide cohort study. J Gastroenterol 2014;49:923-931.
4. Turumin JL, Shanturov VA, Turumina HE. The role of the gallbladder in humans. Rev Gastroenterol Mex 2013;78:177-187.
5. Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, Koshiol J. Gallstones, cholecystectomy, and risk of digestive system cancers. Ann J Epidemiol 2014;179:731-739.
6. Freedman J, Ye W, Näslund E, Lagergren J. Association between cholecystectomy and adenocarcinoma of the esophagus. Br J Surg 2011;98:1133-1137.
7. Manifold RK, Anggiansah A, Owen WJ. Effect of cholecystectomy on gastrointestinal reflex. Am J Gastroenterol 2000;95:2746-2750.
8. Sonne DP, Hare KJ, Martens P, Rehfildt JF, Holst JJ, Vilsbøll T, et al. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastroin-test Liver Physiol 2013;304:G413-G419.
9. McDowell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD. The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 2002;97:2189-2192.
10. Madácsy L, Toftdahl DB, Middelfart HV, Hojgaard L, Funch-Jensen P. Comparison of the dynamics of bile emptying by quantitative hepatobiliary scintigraphy before and after cholecystectomy in patients with uncomplicated gallstone disease. Clin Nucl Med 1999;24:649-654.
11. Miftode SV, Troja A, El-Sourani N, Karelwa H, Antolovic D. Simultaneous cholecystectomy during gastric and oesophageal resection: a retrospective analysis and critical review of literature. Int J Surg 2014;12:1357-1359.
12. Shin SM. Cholecystectomy and the risk of alimentary tract cancers: a systematic review. World J Gastroenterol 2015;21:3679-3693.
13. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005;589:47-65.
14. Mutalas SV, Troja A, El-Sourani N, Raab HR, Antolovic D. Simultaneous cholecystectomy during gastric and oesophageal resection: a retrospective analysis and critical review of literature. Int J Surg 2014;12:1357-1359.
15. Yi SQ, Ren K, Kinoshita M, Takano N, Itoh M, Ozaki N. Innervation of extrahepatic biliary tract, with special reference to the direct bidirectional neural connections of the gall bladder, sphincter of Oddi and duodenum in suncus murinus, in whole-mount immunohistochemical study. Anat Histol Embryol 2016;45:184-188.
16. Atak I, Ozdil K, Yücel M, Caliskan M, Kilic A, Erdem H, et al. The effect of laparoscopic cholecystectomy on the development of alkaline reflux gastritis and intestinal metaplasia. Hepatogastroenterology 2012;59:59-61.
17. Freedman J, Lagergren J, Bergström R, Näslund E, Nyrén O. Cholecystectomy, peptic ulcer disease and the risk of adenocarcinoma of the esophagus and gastric cardia. Br J Surg 2000;87:1087-1093.
18. Bueno de Mesquita HB, Mauisonneuve P, Moerman CJ, Walker AM. Aspects of medical history and exocrine carcinoma of the pancreas: a population-based case-control study in The Netherlands. Int J Cancer 1992;52:17-23.
19. Fall K, Ye W, Nyrën O. Risk for gastric cancer after cholecystectomy. Am J Epidemiol 2000;152:548-553.
20. Faden DP, Hare KJ, Martens P, Rehfildt JF, Holst JJ, Vilsbo T, et al. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. Am J Physiol Gastrointestinal Liver Physiol 2013;304:G413-G419.
21. McDowell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD. The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 2002;97:2189-2192.
22. Madácsy L, Toftdahl DB, Middelfart HV, Hojgaard L, Funch-Jensen P. Comparison of the dynamics of bile emptying by quantitative hepatobiliary scintigraphy before and after cholecystectomy in patients with uncomplicated gallstone disease. Clin Nucl Med 1999;24:649-654.